CLZ-8

CLZ-8 (Compound 8) is an orally active Mcl-1-PUMA interface inhibitor, with a Ki of 0.3 μM. CLZ-8 exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells[1].

Product Specifications

CAS Number

[678158-55-9]

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/clz-8.html

Purity

99.14

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N=C(N2CCN(CCO)CC2)S/C1=C\C3=CC=C(C4=CC=CC=C4)C=C3

Molecular Formula

C22H23N3O2S

Molecular Weight

393.50

References & Citations

[1]Liu J, et al. Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound. Oncotarget. 2017 Apr 20;8 (33) :54236-54242.|[2]Feng T, et al. CLZ-8, a potent small-molecular compound, protects radiation-induced damages both in vitro and in vivo. Environ Toxicol Pharmacol. 2018 Jul;61:44-51.